AGEN - Agenus Inc Stock Price, Fair Value and News

10.86USD+0.36 (+3.43%)Market Closed

Market Summary

USD10.86+0.36

Market Closed

3.43%

AGEN Stock Price

View Fullscreen

AGEN RSI Chart

AGEN Valuation

Market Cap

228.1M

Price/Earnings (Trailing)

-0.91

Price/Sales (Trailing)

1.41

EV/EBITDA

-1.7

Price/Free Cashflow

-1.08

AGEN Price/Sales (Trailing)

AGEN Profitability

Operating Margin

99.43%

EBT Margin

-74.77%

Return on Equity

131.35%

Return on Assets

-97.44%

Free Cashflow Yield

-92.97%

AGEN Fundamentals

AGEN Revenue

Revenue (TTM)

161.4M

Rev. Growth (Yr)

22.28%

Rev. Growth (Qtr)

-66.58%

AGEN Earnings

Earnings (TTM)

-250.0M

Earnings Growth (Yr)

10.49%

Earnings Growth (Qtr)

-30.61%

Breaking Down AGEN Revenue

Last 7 days

3.5%

Last 30 days

101.1%

Last 90 days

-17.7%

Trailing 12 Months

-61.8%

How does AGEN drawdown profile look like?

AGEN Financial Health

Current Ratio

0.24

AGEN Investor Care

Shares Dilution (1Y)

20.38%

Diluted EPS (TTM)

-12.54

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	161.4M	0	0	0
2023	95.0M	99.4M	100.9M	156.3M
2022	309.9M	320.1M	89.9M	98.0M
2021	84.8M	68.5M	306.7M	295.7M
2020	85.3M	96.5M	91.4M	88.2M
2019	115.0M	114.9M	122.0M	150.0M
2018	41.4M	39.8M	38.3M	36.8M
2017	43.6M	41.2M	40.1M	42.9M
2016	26.8M	27.0M	24.6M	22.6M
2015	10.2M	13.5M	18.8M	24.8M
2014	2.7M	4.9M	5.8M	7.0M
2013	3.7M	3.9M	3.7M	3.0M
2012	15.5M	15.3M	15.5M	16.0M
2011	3.1M	3.1M	3.1M	2.8M
2010	0	3.3M	3.4M	3.4M
2009	0	0	0	3.3M

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Agenus Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
May 03, 2024	armen garo h	acquired	16,311	13.07	1,248	see remarks
Apr 19, 2024	armen garo h	acquired	16,354	5.31	3,080	see remarks
Apr 05, 2024	armen garo h	acquired	16,348	0.5	32,697	see remarks
Mar 22, 2024	armen garo h	acquired	14,939	0.55	27,163	see remarks
Mar 08, 2024	armen garo h	acquired	14,831	0.67	22,136	see remarks
Feb 23, 2024	armen garo h	acquired	14,834	0.68	21,815	see remarks
Feb 15, 2024	armen garo h	bought	324,050	0.6481	500,000	see remarks
Feb 09, 2024	armen garo h	acquired	14,833	0.75	19,778	see remarks
Jan 26, 2024	armen garo h	acquired	14,833	0.66	22,475	see remarks
Jan 12, 2024	armen garo h	acquired	14,833	0.64	23,177	see remarks

Which funds bought or sold AGEN recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 17, 2024	Artal Group S.A.	unchanged	-	-3,874,880	9,066,120	0.23%
May 16, 2024	CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM	reduced	-89.05	-267,501	22,224	-%
May 16, 2024	JANE STREET GROUP, LLC	reduced	-75.62	-776,572	159,923	-%
May 16, 2024	Virtus Investment Advisers, Inc.	sold off	-100	-85,698	-	-%
May 16, 2024	COMERICA BANK	added	112	380	1,160	-%
May 16, 2024	Creekmur Asset Management LLC	unchanged	-	-620	1,450	-%
May 15, 2024	Squarepoint Ops LLC	sold off	-100	-10,584	-	-%
May 15, 2024	MILLENNIUM MANAGEMENT LLC	reduced	-68.14	-5,390,990	1,549,250	-%
May 15, 2024	CAPTRUST FINANCIAL ADVISORS	new	-	129,291	129,291	-%
May 15, 2024	Mariner, LLC	added	1.84	-9,396	23,390	-%

Are Funds Buying or Selling AGEN?

Are funds buying AGEN calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own AGEN

No. of Funds

Unveiling Agenus Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 21, 2024	point72 asset management, l.p.	6.8%	28,268,112	SC 13G
Feb 14, 2024	deep track capital, lp	8.31%	31,697,539	SC 13G/A
Feb 13, 2024	vanguard group inc	7.93%	30,266,890	SC 13G/A
Feb 09, 2024	artal international s.c.a.	4.1%	15,631,235	SC 13G/A
Jan 25, 2024	blackrock inc.	8.5%	32,236,488	SC 13G/A
Jan 22, 2024	state street corp	2.28%	8,680,267	SC 13G/A
Feb 14, 2023	deep track capital, lp	8.86%	2.7e+07	SC 13G/A
Feb 09, 2023	state street corp	7.42%	22,603,650	SC 13G/A
Feb 09, 2023	vanguard group inc	7.97%	24,281,255	SC 13G/A
Feb 03, 2023	blackrock inc.	8.3%	23,400,423	SC 13G/A

Recent SEC filings of Agenus Inc

View All Filings

Date Filed	Form Type	Document
May 07, 2024	10-Q	Quarterly Report
May 07, 2024	4	Insider Trading
May 07, 2024	8-K	Current Report
May 07, 2024	8-K	Current Report
Apr 26, 2024	ARS	ARS
Apr 26, 2024	DEF 14A	DEF 14A
Apr 22, 2024	4	Insider Trading
Apr 22, 2024	4	Insider Trading
Apr 22, 2024	4	Insider Trading
Apr 22, 2024	4	Insider Trading

Peers (Alternatives to Agenus Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	50.9B	6.8B	28.49%	6.05%	-8.53	7.44	-64.45%	-224.75%
HILS	22.5B	216.3K	-0.77%	465779.94%	-2.5K	104.0K	-	-8.13%
ALNY	18.9B	2.0B	2.79%	-21.33%	-56.9	9.43	75.20%	68.82%
BMRN	14.7B	2.5B	-14.30%	-15.94%	71.65	5.96	13.74%	186.89%
INCY	12.8B	3.8B	8.33%	-10.25%	17.2	3.4	8.58%	129.81%
MID-CAP
BBIO	5.6B	107.9M	20.58%	115.45%	-10.31	48.09	54.84%	-28.31%
APLS	5.0B	524.1M	-13.99%	-52.79%	-12.02	9.57	394.93%	39.61%
AXSM	3.6B	251.0M	9.96%	-0.29%	-12.28	14.5	73.58%	-86.73%
ARWR	3.1B	240.7M	9.94%	-31.73%	-6.53	12.77	-1.03%	-213.43%
ACAD	2.4B	813.8M	-14.08%	-36.34%	-1.4K	3	56.43%	98.83%
SMALL-CAP
CPRX	1.9B	411.3M	3.06%	35.16%	29.91	4.73	60.38%	-34.49%
NVAX	1.8B	996.6M	234.45%	75.34%	-4.58	1.83	-26.66%	65.49%
CRBP	480.9M	881.7K	21.10%	351.81%	-14.25	481.06	-77.61%	33.36%
INO	310.9M	4.9M	8.40%	53.85%	-2.49	63.89	-54.97%	48.23%
IBIO	17.1M	2.1M	4.76%	108.64%	-0.74	7.61	-13.45%	69.54%

Agenus Inc News

Latest updates

Agenus Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Revenue	-66.6%	28,005,000	83,801,500	24,314,000	25,296,000	22,902,000	28,385,500	22,772,000	20,926,000	25,941,000	20,261,000	252,954,000	10,730,000	11,719,000	31,265,000	14,832,000	26,945,000	15,128,000	34,502,000	19,940,000	15,715,000	79,891,000
Cost Of Revenue	-58.8%	107,000	260,000	303,000	254,000	2,294,000	7,693,000	308,000	2,024,000	543,000	881,000	817,000	667,000	1,105,000	-	911,000	634,000	-	-	-	-	-
S&GA Expenses	-100.0%	-	21,177,500	18,909,000	20,415,000	18,237,000	25,035,500	18,105,000	18,914,000	18,953,000	21,971,500	21,385,000	16,650,000	16,352,000	20,030,000	14,380,000	14,195,000	10,613,000	12,318,500	11,512,000	11,405,000	10,805,000
R&D Expenses	-34.2%	43,925,000	66,723,000	51,443,000	59,285,000	57,118,000	53,278,500	46,011,000	44,960,000	42,442,000	53,486,000	42,937,000	45,508,000	36,677,000	35,569,500	32,134,000	38,550,000	36,363,000	36,833,500	46,132,000	45,243,000	40,130,000
EBITDA Margin	3.8%	-0.64	-0.66	-1.07	-1.10	-1.17	-1.15	-1.26	-0.35	-0.36	-0.38	-0.37	-	-	-	-	-	-	-	-	-	-
Interest Expenses	4.9%	667,000	636,000	827,000	875,000	830,000	296,000	279,000	289,000	279,000	290,000	285,000	299,000	278,000	284,000	302,000	386,000	204,000	299,000	305,000	308,000	312,000
EBT Margin	3.2%	-0.75	-0.77	-1.20	-1.21	-1.27	-1.23	-1.34	-0.38	-0.39	-0.41	-0.39	-	-	-	-	-	-	-	-	-	-
Net Income	-30.6%	-63,454,000	-48,582,000	-64,532,000	-73,430,000	-70,893,000	-74,101,670	-56,715,000	-49,235,000	-50,604,000	-67,606,733	177,277,000	-83,991,000	-54,403,000	-37,660,000	-51,646,000	-48,244,000	-45,271,000	-30,107,000	-45,526,000	-50,686,000	18,454,000
Net Income Margin	6.0%	-1.55	-1.65	-2.80	-2.77	-2.64	-2.35	-2.49	0.03	-0.08	-0.10	0.00	-	-	-	-	-	-	-	-	-	-
Free Cashflow	5.9%	-38,226,000	-40,625,000	-68,683,000	-64,480,000	-60,368,000	-61,684,000	-47,911,000	-61,905,000	-56,935,000	-31,889,000	108,987,000	-	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Assets	-18.3%	257	314	335	384	413	414	429	456	441	466	438	192	235	215	204	186	180	155	175	207	246
Current Assets	-46.3%	60.00	112	126	171	206	213	251	289	290	332	308	93.00	136	114	125	105	103	87.00	107	139	179
Cash Equivalents	-30.5%	53.00	76.00	6.00	11.00	15.00	179	208	228	248	292	257	74.00	119	100	114	79.00	92.00	62.00	93.00	122	158
Inventory	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0.00	0.00	0.00
Net PPE	-2.3%	130	133	140	143	140	133	101	89.00	76.00	60.00	50.00	29.00	27.00	27.00	27.00	29.00	28.00	26.00	25.00	26.00	26.00
Goodwill	-0.1%	25.00	25.00	25.00	25.00	26.00	25.00	24.00	24.00	25.00	25.00	25.00	25.00	24.00	25.00	25.00	24.00	23.00	23.00	23.00	23.00	23.00
Current Liabilities	0.0%	256	256	198	204	191	189	173	160	163	157	150	169	138	130	147	142	127	122	133	122	106
Long Term Debt	-100.0%	-	13.00	13.00	13.00	13.00	13.00	-	-	-	13.00	13.00	19.00	19.00	19.00	19.00	19.00	13.00	13.00	-	-	-
LT Debt, Current	9197.9%	14.00	0.00	0.00	1.00	1.00	1.00	13.00	14.00	14.00	1.00	1.00	1.00	1.00	1.00	1.00	2.00	1.00	1.00	14.00	14.00	14.00
LT Debt, Non Current	-100.0%	-	13.00	13.00	13.00	13.00	13.00	-	-	-	13.00	13.00	19.00	19.00	19.00	19.00	19.00	13.00	13.00	-	-	-
Shareholder's Equity	-28.3%	-190	-148	-	-	-53.11	-54.90	-	14.00	28.00	48.00	36.00	-	-	-	-	-	-	-	-	-	-
Retained Earnings	-3.2%	-2,017	-1,955	-1,909	-1,847	-1,778	-1,709	-1,600	-1,584	-1,538	-1,489	-1,424	-1,602	-1,519	-1,465	-1,400	-1,377	-1,329	-0.02	-1,254	-1,209	-1,158
Additional Paid-In Capital	1.4%	1,817	1,792	1,777	1,751	1,715	1,645	1,615	1,583	1,550	1,520	1,464	1,353	1,329	1,258	1,227	1,156	1,132	1,060	1,055	1,052	1,044
Accumulated Depreciation	5.1%	65.00	62.00	61.00	58.00	56.00	54.00	53.00	52.00	52.00	51.00	49.00	50.00	48.00	47.00	46.00	45.00	44.00	43.00	42.00	40.00	39.00
Shares Outstanding	-	-	-	-	-	-	-	-	-	-	-	-	11.00	-	-	8.00	9.00	7.00	-	7.00	-	-
Minority Interest	-7.0%	11.00	12.00	14.00	16.00	5.00	6.00	9.00	10.00	12.00	13.00	-6.30	-8.63	-8.29	-7.83	-7.83	-7.34	-6.58	-5.98	-5.18	-4.38	-3.15
Float	-	-	-	-	584	-	-	-	544	-	-	-	1,230	-	-	-	671	-	-	-	407	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Cashflow From Operations	5.5%	-38,191	-40,402	-65,231	-60,043	-58,526	-47,338	-32,191	-43,453	-52,391	-22,927	131,373	-55,557	-42,744	-35,590	-31,626	-37,375	-34,505	-31,780	-66,087	40,900	76,587
Share Based Compensation	-24.0%	4,152	5,461	5,881	6,042	5,485	4,259	4,453	4,634	4,991	5,198	4,790	5,588	4,001	2,744	2,723	2,553	2,397	3,048	3,084	1,917	1,843
Cashflow From Investing	-91.9%	229	2,824	11,548	517	-11,489	-6,383	-15,636	-4,058	-7,533	-13,299	-27,385	-2,270	-196	-834	-873	-2,090	-644	-1,056	-839	-1,261	-1,501
Cashflow From Financing	102.7%	14,830	7,315	18,038	38,263	56,250	23,773	28,223	27,796	16,038	71,605	78,905	11,792	62,962	24,647	67,283	26,312	65,613	1,268	34.00	-76.00	30,097
Buy Backs	-100.0%	-	42.00	1,221	640	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

AGEN Income Statement

2024-03-31

Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Revenue:
Total revenues	$ 28,005	$ 22,902
Operating expenses:
Cost of service revenue	(107)	(2,294)
Research and development	(43,925)	(57,118)
General and administrative	(16,855)	(18,237)
Contingent purchase price consideration fair value adjustment	0	406
Operating loss	(32,882)	(54,341)
Other income (expense):
Non-operating income (expense)	(1,106)	40
Interest expense, net	(29,466)	(16,592)
Net loss	(63,454)	(70,893)
Dividends on Series A-1 convertible preferred stock	(54)	(53)
Net loss attributable to non-controlling interest	(1,568)	(2,639)
Net loss attributable to Agenus Inc. common stockholders	$ (61,940)	$ (68,307)
Per common share data:
Basic net loss attributable to Agenus Inc. common stockholders	$ (3.04)	$ (4.31)
Diluted net loss attributable to Agenus Inc. common stockholders	$ (3.04)	$ (4.31)
Weighted average number of Agenus Inc. common shares outstanding:
Basic	20,368	15,855
Diluted	20,368	15,855
Other comprehensive income (loss):
Foreign currency translation income (loss)	$ (116)	$ 2
Other comprehensive income (loss)	(116)	2
Comprehensive loss	(62,056)	(68,305)
Research and Development [Member]
Revenue:
Total revenues	0	2,612
Service Revenue [Member]
Revenue:
Total revenues	238	1,184
Non-Cash Royalty Revenue Related to the Sale of Future Royalties [Member]
Revenue:
Total revenues	$ 27,767	$ 19,106

AGEN Balance Sheet

2024-03-31

Condensed Consolidated Balance Sheets (Unaudited) - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
ASSETS
Cash and cash equivalents	$ 52,856	$ 76,110
Accounts receivable	476	25,836
Prepaid expenses	3,895	8,098
Other current assets	3,125	2,372
Total current assets	60,352	112,416
Property, plant and equipment, net of accumulated amortization and depreciation of $65,080 and $61,943 at March 31, 2024 and December 31, 2023, respectively	130,330	133,421
Operating lease right-of-use assets	29,340	29,606
Goodwill	24,698	24,723
Acquired intangible assets, net of accumulated amortization of $17,799 and $17,688 at March 31, 2024 and December 31, 2023, respectively	4,230	4,411
Other long-term assets	7,609	9,336
Total assets	256,559	313,913
LIABILITIES AND STOCKHOLDERS' DEFICIT
Current portion, long-term debt	13,575	146
Current portion, liability related to sale of future royalties and milestones	133,588	132,502
Current portion, deferred revenue	13	18
Current portion, operating lease liabilities	2,811	2,587
Accounts payable	50,693	61,446
Accrued liabilities	41,291	45,283
Other current liabilities	14,031	13,915
Total current liabilities	256,002	255,897
Long-term debt, net of current portion	0	12,768
Liability related to sale of future royalties and milestones, net of current portion	125,249	124,556
Deferred revenue, net of current portion	1,143	1,143
Operating lease liabilities, net of current portion	61,756	62,511
Other long-term liabilities	2,732	5,420
Commitments and contingencies
STOCKHOLDERS" DEFICIT
Common stock, par value $0.01 per share; 800,000,000 shares authorized; 20,994,143 and 19,718,662 shares issued at March 31, 2024 and December 31, 2023, respectively	210	197
Additional paid-in capital	1,816,985	1,796,095
Accumulated other comprehensive loss	(1,071)	(955)
Accumulated deficit	(2,017,554)	(1,955,668)
Total stockholders' deficit attributable to Agenus Inc.	(201,430)	(160,331)
Non-controlling interest	11,107	11,949
Total stockholders' deficit	(190,323)	(148,382)
Total liabilities and stockholders' deficit	256,559	313,913
Series A-1 convertible preferred stock [Member]
STOCKHOLDERS" DEFICIT
Series A-1 convertible preferred stock; 31,620 shares designated, issued, and outstanding at March 31, 2024 and December 31, 2023; liquidation value of $33,940 at March 31, 2024	$ 0	$ 0

About Agenus Inc

Agenus Inc., a clinical-stage immuno-oncology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies. It develops QS-21 Stimulon adjuvant, a saponin-based vaccine adjuvant. The company also develops Balstilimab, an anti-PD-1 antagonist that has completed Phase II clinical trial to treat second line cervical cancer; AGEN1181, an anti-CTLA-4 monospecific antibody that is in Phase 2 clinical trial; AGEN2373, a CD137 monospecific antibody that is in Phase 1b clinical trial; AGEN1423, a tumor microenvironment conditioning anti-CD73/TGFÃƒÅ¸ TRAP bi-functional antibody that has completed Phase 1 clinical trial; AGEN1571, an ILT2 monospecific antibody that is in Phase 1 clinical trial; BMS-986442, a TIGIT bispecific antibodies; and AGEN1327, a human monoclonal antibody. In addition, it develops INCAGN1876, a GITR monospecific antibody; INCAGN2390, a TIM-3 monospecific antibody; INCAGN2385, a LAG-3 monospecific antibody; MK-4830, a monospecific antibody targeting ILT4; UGN-301, a zalifrelimab intravesical solution for the treatment of cancers of the urinary tract that is in a Phase 1 clinical trial; AGENT 797, an iNKT cells that is in Phase 1 clinical trial for solid tumors, multiple myeloma, and viral ARDS; and AGEN1884, a first-generation anti-CTLA-4 monospecific antibody. The company operates under Agenus, MiNK, Prophage, Retrocyte Display, and Stimulon trademarks. It has collaborations with Bristol-Myers Squibb Company, Betta Pharmaceuticals Co., Ltd., Incyte Corporation, Merck Sharpe & Dohme, and Gilead Sciences, Inc. The company was formerly known as Antigenics Inc. and changed its name to Agenus Inc. in January 2011. Agenus Inc. was founded in 1994 and is headquartered in Lexington, Massachusetts.

CEO	Dr. Garo H. Armen Ph.D.
WEBSITE	agenusbio.com
INDUSTRY	Biotechnology
EMPLOYEES	533

Agenus Inc Frequently Asked Questions

What is the ticker symbol for Agenus Inc? What does AGEN stand for in stocks?

AGEN is the stock ticker symbol of Agenus Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Agenus Inc (AGEN)?

As of Fri May 17 2024, market cap of Agenus Inc is 228.05 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of AGEN stock?

You can check AGEN's fair value in chart for subscribers.

What is the fair value of AGEN stock?

You can check AGEN's fair value in chart for subscribers. The fair value of Agenus Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Agenus Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for AGEN so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Agenus Inc a good stock to buy?

The fair value guage provides a quick view whether AGEN is over valued or under valued. Whether Agenus Inc is cheap or expensive depends on the assumptions which impact Agenus Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for AGEN.

What is Agenus Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri May 17 2024, AGEN's PE ratio (Price to Earnings) is -0.91 and Price to Sales (PS) ratio is 1.41. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. AGEN PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Agenus Inc's stock?

In the past 10 years, Agenus Inc has provided -0.144 (multiply by 100 for percentage) rate of return.